香丹注射液联合酒石酸美托洛尔对冠心病心绞痛患者临床症状及氧化应激反应的影响

doi:10.3760/cma.j.cn441417-20240808-09022

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (9): 1520-1524.DOI: 10.3760/cma.j.cn441417-20240808-09022

香丹注射液联合酒石酸美托洛尔对冠心病心绞痛患者临床症状及氧化应激反应的影响

臧柯靓¹ 班芳¹ 张秋梅² 张恒亮³

¹商丘市立医院心血管内科，商丘 476100；²商丘市第一人民医院冠心病监护病房（CCU病房），商丘 476100；³商丘市第一人民医院心血管内科，商丘 476100

收稿日期:2024-08-08 出版日期:2025-05-01 发布日期:2025-05-20
通讯作者: 臧柯靓，Email：15738111769@163.com
基金资助:
河南省医学科技攻关计划（LHGJ20230458）

The effect of Xiangdan injection combined with metoprolol tartrate on clinical symptoms and oxidative stress response in patients with coronary heart disease and angina pectoris

Zang Keliang¹, Ban Fang¹, Zhang Qiumei², Zhang Hengliang³

¹Department of Cardiovascular Medicine, Shangqiu Municipal Hospital, Shangqiu 476100, China; ²Coronary Care Unit (CCU), The First People's Hospital of Shangqiu, Shangqiu 476100, China; ³Department of Cardiovascular Medicine, The First People's Hospital of Shangqiu, Shangqiu 476100, China

Received:2024-08-08 Online:2025-05-01 Published:2025-05-20
Contact: Zang Keliang, Email:15738111769@163.com
Supported by:
Henan Province Medical Science and Technology Research Plan (LHGJ20230458)

摘要/Abstract

摘要：

目的　分析香丹注射液联合酒石酸美托洛尔治疗冠心病心绞痛患者的效果，及其对临床症状和氧化应激反应的影响。方法　选取2021年4月至2024年4月商丘市立医院收治的92例冠心病心绞痛患者作为研究对象。采用随机数字表法，将患者分为对照组（46例）和研究组（46例）。对照组男25例，女21例；年龄51～78（64.29±7.08）岁；冠心病病程2～10（6.24±1.66）年。研究组男22例，女24例；年龄52～79（65.36±7.17）岁；冠心病病程2～11（6.51±1.84）年。对照组采用酒石酸美托洛尔治疗，研究组采用香丹注射液联合酒石酸美托洛尔治疗。比较两组临床疗效；治疗前后临床症状（心绞痛发作频率、持续时间）、心肌损伤标志物［脑钠肽（BNP）、肌酸激酶同工酶（CK-MB）、心肌肌钙蛋白Ⅰ（cTnⅠ）］和氧化应激指标［丙二醛（MDA）、过氧化氢酶（CAT）、超氧化物歧化酶（SOD）］水平；不良反应（头晕、恶心、疲劳等）。采用独立样本t检验、配对t检验和χ2检验进行统计学分析。结果　研究组治疗总有效率高于对照组［89.13%（41/46）比71.74%（33/46）］（P<0.05）。治疗后，研究组心绞痛发作频率低于对照组［（2.49±0.62）次/周比（3.25±0.68）次/周］，心绞痛持续时间短于对照组［（5.05±0.97）min比（6.54±0.39）min］（均P<0.05）；研究组BNP、CK-MB、cTnⅠ水平均低于对照组［（114.72±16.87）ng/L比（143.59±18.04）ng/L、（15.27±2.21）U/L比（18.67±2.16）U/L、（1.21±0.27）μg/L比（1.46±0.26）μg/L］（均P<0.05）；研究组MDA水平低于对照组［（6.24±1.29）mol/L比（8.27±1.46）mol/L］，CAT和SOD水平均高于对照组［（34.97±4.38）U/ml比（30.67±4.21）U/ml、（98.46±7.64）U/L比（90.37±7.92）U/L］（均P<0.05）。两组不良反应总发生率比较，差异无统计学意义（P>0.05）。结论　香丹注射液联合酒石酸美托洛尔治疗冠心病心绞痛患者效果较好，有助于改善临床症状，减轻氧化应激损伤，改善心肌受损状况，安全性较好。

关键词: 冠心病心绞痛, , , 香丹注射液, , , 酒石酸美托洛尔, , , 临床症状, , , 氧化应激

Abstract:

Objective　To analyze the efficacy of Xiangdan injection combined with metoprolol tartrate in patients with coronary heart disease and angina pectoris, as well as its impact on clinical symptoms and oxidative stress response. Methods　A total of 92 patients with angina pectoris of coronary heart disease who were admitted to Shangqiu Municipal Hospital from April 2021 to April 2024 were selected as the research subjects. The patients were divided into the control group (46 cases) and the research group (46 cases) by using the random number table method. There were 25 males and 21 females in the control group, aged 51-78(64.29±7.08) years, course of coronary heart disease 2-10(6.24±1.66) years. There were 22 males and 24 females in the research group, aged 52-79(65.36±7.17) years, course of coronary heart disease 2-11(6.51±1.84) years. The control group was treated with metoprolol tartrate, and the research group was treated with Xiangdan injection combined with metoprolol tartrate. Compare the clinical efficacy of the two groups; clinical symptoms (frequency and duration of angina pectoris attacks), levels of myocardial injury markers [creatine kinase MB (CK-MB), brain natriuretic peptide (BNP), cardiac troponin Ⅰ (cTnⅠ)], and oxidative stress indicators [superoxide dismutase (SOD), catalase (CAT), malondialdehyde (MDA)] before and after treatment; and adverse reactions (vertigo, nausea, fatigue, etc.). Independent sample t test, paired t test, and χ² test were used for statistical analysis. Results　The total effective rate of treatment in the research group was higher than that in the control group[89.13% (41/46) vs. 71.74% (33/46)](P<0.05). After the treatment, the frequency of angina pectoris attacks in the research group was lower than that in the control group[(2.49±0.62) times/week vs. (3.25±0.68) times/week] and the duration of angina pectoris was shorter than that of the control group[(5.05±0.97) min vs. (6.54±0.39) min] (both P<0.05); the levels of BNP, CK-MB and cTnⅠ in the research group were lower than those in the control group [(114.72±16.87) ng/L vs. (143.59±18.04) ng/L, (15.27±2.21) U/L vs. (18.67±2.16) U/L, (1.21±0.27) μg/L vs. (1.46±0.26) μg/L] (all P<0.05); the MDA level in the research group was lower than that in the control group [(6.24±1.29) mol/L vs. (8.27±1.46) mol/L] and the levels of CAT and SOD were higher than those of the control group [(34.97±4.38) U/ml vs. (30.67±4.21) U/ml, (98.46±7.64) U/L vs. (90.37±7.92) U/L](all P<0.05). There were no statistically significant difference in the total incidence rate of adverse reactions between the two groups (P>0.05). Conclusion　Xiangdan injection combined with metoprolol tartrate has significant effect in treating angina pectoris in coronary heart disease, which helps to improve the symptoms of angina pectoris, reduce oxidative stress damage, improve myocardial damage, and has high safety.

臧柯靓班芳张秋梅张恒亮.

香丹注射液联合酒石酸美托洛尔对冠心病心绞痛患者临床症状及氧化应激反应的影响 [J]. 国际医药卫生导报, 2025, 31(9): 1520-1524.

Zang Keliang, Ban Fang, Zhang Qiumei, Zhang Hengliang.

The effect of Xiangdan injection combined with metoprolol tartrate on clinical symptoms and oxidative stress response in patients with coronary heart disease and angina pectoris [J]. International Medicine and Health Guidance News, 2025, 31(9): 1520-1524.

参考文献

[1] Mileva N, Nagumo S, Mizukami T, et al. Prevalence of coronary microvascular disease and coronary vasospasm in patients with nonobstructive coronary artery disease: systematic review and meta-analysis[J]. J Am Heart Assoc, 2022, 11(7):e023207. DOI: 10.1161/JAHA.121.023207.

[2]吴威,张婷,蒙奕兵,等.卡维地洛联合尼可地尔治疗老年冠心病心绞痛患者的效果及对sICAM-1和MPO水平的影响[J].中国医药导报,2020,17(18):139-142.DOI:10.20047/j.issn1673-7210.2020.18.034.

[3]边玮婧,董志,戚凤君,等.单硝酸异山梨酯联合酒石酸美托洛尔对老年冠心病心绞痛患者心肌酶谱的影响[J].西北药学杂志,2023,38(4):179-182.DOI:10.3969/j.issn.1004- 2407.2023.04.032.

[4]孙雅萍,宋杨.谷红注射液联合用药治疗冠心病患者PCI术后再发心绞痛的临床疗效及其对炎性因子和血管内皮功能的影响[J].辽宁中医杂志,2020,47(9):66-68.DOI:10.13192/j.issn.1000-1719.2020.09.022.

[5]高海军,陈永,李培,等.香丹注射液联合尼可地尔治疗冠心病稳定型劳力性心绞痛的疗效[J].贵州医科大学学报,2023,48(8):986-992.DOI:10.19367/j.cnki.2096-8388. 2023.08.018.

[6]尹聪,程静,孙辉,等.中药注射液治疗不稳定型心绞痛对患者血脂水平影响系统评价和网状Meta分析[J].辽宁中医药大学学报,2021,23(8):179-189.DOI:10.13194/j.issn. 1673-842x.2021.08.038.

[7]中华中医药学会内科分会心病专业委员会.中医心病之心绞痛诊断与疗效标准[J].中国医药学报,2004,19(10):581-583.DOI:10.3969/j.issn.1673-1727.2004.10.001.

[8]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:68-73.

[9]周付娇,吕勇,张静.丹参酮ⅡA磺酸钠联合尼可地尔治疗冠心病稳定性心绞痛疗效及对心功能改善研究[J].中华老年心脑血管病杂志,2024,26(11):1301-1305.DOI:10.3969/j.issn.1009-0126.2024.11.011.

[10] Wu T, Li S, Li Z, et al. Efficacy and safety ofGinkgo biloba dropping pills in the treatment of coronary heart disease with stable angina pectoris and depression: study protocol for a randomised, placebo-controlled, parallel-group, double-blind and multicentre clinical trial[J]. BMJ Open, 2023, 13(5):e055263. DOI: 10.1136/bmjopen-2021-055263.

[11]付强,邵旭鹏,谢娜,等.心通口服液治疗冠心病心绞痛疗效的Meta分析[J].中国中医急症,2024,33(8):1317-1321.DOI:10.3969/j.issn.1004-745X.2024.08.001.

[12]王新亮.酒石酸美托洛尔缓释片联合阿司匹林对冠心病心绞痛患者QT离散度、血清细胞因子水平的影响[J].检验医学与临床,2022,19(15):2131-2134.DOI:10.3969/j.issn.1672-9455.2022.15.030.

[13]罗娜,齐贵彬.冠心苏合软胶囊联合美托洛尔治疗冠心病心绞痛的临床研究[J].现代药物与临床,2021,36(7):1475-1479.DOI:10.7501/j.issn.1674-5515.2021.07.028.

[14]杨晓宁,仵文强,王兰.血府逐瘀汤联合穴位敷贴治疗冠心病稳定型心绞痛的临床研究[J].转化医学杂志,2024,13(4):645-648.DOI:10.3639/j.issn.2095-3097.2024.04.037.

[15]张静,张恺,易湛苗.丹参酚酸制剂辅助治疗冠心病、心绞痛及脑梗死相关疾病有效性及安全性的系统评价[J].中国药物警戒,2024,21(8):910-915,中插4-中插6,920.DOI:10.19803/j.1672-8629.20230583.

[16]王子杨,刘美志,胡晓贞,等.脉通君安汤治疗气虚血瘀型冠心病心绞痛的临床疗效及转录组学研究[J].南京中医药大学学报,2024,40(4):419-428.DOI:10.14148/j.issn. 1672-0482.2024.0419.

[17]李文大,刘金霞,王雪梅,等.冠心汤治疗冠心病介入术后心绞痛的临床疗效及对患者脂代谢的影响[J].河北中医,2023,45(8):1269-1273.DOI:10.3969/j.issn.1002-2619. 2023.08.009.

[18]贾福运,高晟玮,张瑞,等.中药注射液联合常规西药治疗冠心病稳定型心绞痛的临床疗效及血液流变学影响的网状Meta分析[J].世界科学技术-中医药现代化,2024,26(3):601-616.DOI:10.11842/wst.20230526006.

[19]宋莉平.香丹注射液联合阿托伐他汀治疗对冠心病患者冠脉血流量及心功能的影响[J].临床医学工程,2021,28(6):775-776.DOI:10.3969/j.issn.1674-4659.2021.06.0775.

[20]余琳,武晓灵.香丹注射液联合乌司他丁治疗重症急性胰腺炎的疗效及对血液流变学和血清SOD、CRP、IL-6水平的影响[J].中国中西医结合消化杂志,2021,29(6):421-425.DOI:10.3969/j.issn.1671-038X.2021.06.08.

[21]卓新凤.香丹注射液联合曲美他嗪片对冠心病心绞痛患者疗效及血清炎性因子的影响[J].吉林中医药,2017,37(8):788-791.DOI:10.13463/j.cnki.jlzyy.2017.08.009.

[22]夏振华,滕伟,翟小菊,等.香丹注射液辅助治疗冠心病心绞痛的临床效果[J].实用中西医结合临床,2023,23(22):46-48,104.DOI:10.13638/j.issn.1671-4040.2023.22.013.

[23]李兰霞,王东雁,王蒙,等.红景天注射液与芪苈强心胶囊对冠心病心绞痛患者抗氧化应激指标及心功能的影响[J].中国中西医结合急救杂志,2022,29(1):53-56.DOI:10.3969/j.issn.1008-9691.2022.01.012.

[24]王泽,杜莉,胡梦媛.谷红注射液联合阿托伐他汀治疗冠心病心绞痛患者的临床疗效及其对患者血液流变学和氧化应激影响的研究[J].实用心脑肺血管病杂志,2020,28(S2):12-15.

[25]曹唯仪,付荩毅,李睿,等.基于网络药理学和分子对接探讨丹参治疗冠心病和脑卒中的"异病同治"作用机制研究[J].中西医结合心脑血管病杂志,2024,22(4):582-584,586-590.DOI:10.12102/j.issn.1672-1349.2024.04.002.

[26]许志亮,卢健棋,黄溥玮,等.基于数据分析中药降香治疗冠心病作用机制及药理研究进展[J].辽宁中医药大学学报,2020,22(10):70-75.DOI:10.13194/j.issn.1673- 842x. 2020.10.018.

香丹注射液联合酒石酸美托洛尔对冠心病心绞痛患者临床症状及氧化应激反应的影响

The effect of Xiangdan injection combined with metoprolol tartrate on clinical symptoms and oxidative stress response in patients with coronary heart disease and angina pectoris

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	赵洲刘为朋李宗睿王睿智胡宝光. 高血压大鼠模型的研究现状 [J]. 国际医药卫生导报, 2025, 31(9): 1465-1470.
[2]	吴亚莉付小平丁大为徐宁安周源源. 儿童注意缺陷多动障碍相关危险因素及预测模型构建 [J]. 国际医药卫生导报, 2025, 31(9): 1489-1494.
[3]	汪青园方元龙王智琴黄蓉田松原丽科葛午平朱小春肖尚杰周佳亮. 新生儿坏死性小肠结肠炎保守治疗后继发肠狭窄诊治分析 [J]. 国际医药卫生导报, 2025, 31(9): 1495-1498.
[4]	邓巧妮常亚娜周晓玉康华. 新生儿呼吸窘迫综合征机械通气撤机失败的预警模型构建 [J]. 国际医药卫生导报, 2025, 31(9): 1499-1505.
[5]	张森山蔡美孙锋. 新生儿ABO溶血病中血清总胆红素、脐血胆红素水平及网织红细胞计数对神经系统损害的预测价值 [J]. 国际医药卫生导报, 2025, 31(9): 1506-1510.
[6]	张珂刘景刚吴瑞荣冯慧. 局部枸橼酸钠联合小剂量肝素钠抗凝在脓毒症并急性肾损伤患者CRRT中的应用价值 [J]. 国际医药卫生导报, 2025, 31(9): 1516-1520.
[7]	江正发王立友张晓徐宏勇. 药物涂层球囊成形术后冠心病患者靶血管再狭窄的危险因素研究及预测模型分析 [J]. 国际医药卫生导报, 2025, 31(9): 1525-1531.
[8]	潘希安张远金张国富李俊孙法瑞刘炳霞. 人工智能技术在膝单髁置换术前规划中的应用分析 [J]. 国际医药卫生导报, 2025, 31(9): 1532-1537.
[9]	张婷郭淋张驰付瑞崔治权康晓刚. 青少年双相情感障碍患者血脂水平与区域性脑结构的相关性研究 [J]. 国际医药卫生导报, 2025, 31(9): 1538-1543.
[10]	李岩赵丽敏曲姗姗. 帕罗西汀联合茴拉西坦治疗老年抑郁症的疗效分析 [J]. 国际医药卫生导报, 2025, 31(9): 1544-1548.
[11]	杨玉凤卢立军邓倩陈士东王慧颖. 艾司西酞普兰联合舒肝解郁胶囊对老年抑郁症伴失眠的影响 [J]. 国际医药卫生导报, 2025, 31(9): 1549-1553.
[12]	潘祁喻莉张安生. 铸瓷嵌体冠在短基牙后牙修复患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(9): 1554-1558.
[13]	陈春桃区秀丽李彩霞刘彩玲曾娜芬杜真萍蔡少娜米谦符霞. 维持性血液透析患者自体动静脉内瘘瘤样扩张防治不足影响因素的质性研究 [J]. 国际医药卫生导报, 2025, 31(9): 1559-1564.
[14]	陈娟娟. 中线导管在住院病区患者静脉治疗中的应用现状 [J]. 国际医药卫生导报, 2025, 31(9): 1565-1568.
[15]	魏欣妍魏文娟可易弘钱海兵. 基于授权赋能理论的健康教育在类风湿性关节炎患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(9): 1569-1573.